Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Stock Information for Revelation Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revelation Biosciences Inc.

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.